The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -63.83 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.59 — no flag raisedOK
- Earnings quality 43/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Lexaria Bioscience Corp. reports it. History and quarterly detail are in the app.
- IP Licensing$696K
- B2B$10K
Leadership changes
From Lexaria Bioscience Corp.'s own filings, the day they're filed.
- Richard Christopher · Chairman · appointmenteff. 2024-08-31
- Nelson Cabatuan · CEO · departureeff. 2024-07-15
- Nelson Cabatuan · Chief Financial Officer · appointmenteff. 2024-03-14
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-13
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Lexaria Bioscience Corp., every answer cited to the official filings🔒
- The Intelligence Brief — added when Lexaria Bioscience Corp.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.